Eisai and Biogen plunge after report of second death in groundbreaking Alzheimer’s drug trial
A 65-year-old woman has died of a brain hemorrhage, the second person to die during the Alzheimer’s drug trial. As there are few treatment options, analysts think lecanemab will move forward.
By Naomi Kresge, bloomberg
Eisai Co shares fell the most in about 16 months following a report of a second death potentially linked to the groundbreaking experimental drug for Alzheimer’s disease it’s developing with Biogen Inc.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
